State Medicaid Expansion Policies were Associated with Reduced Rates of Congenital Syphilis, 2008-2022

Authors: Austin M Williams, PhD[1]

1. Independent researcher

Abstract

Objective:

To assess the relationship between adoption of Medicaid expansion policies and rates of congenital syphilis (CS) in the United States.

Study Setting and Design:

Cases of CS have increased nearly 10-fold in the past decade. State (and D.C.) adoptions of Medicaid expansion, State Plan Amendment (SPA) optional family planning eligibility groups, and Medicaid section 1115 waiver demonstration projects have increased eligibility for family planning services. The primary outcome was the state level annual reported rate of CS per 100,000 live births. We assessed two binary policy "treatments" of interest: 1) whether a state had adopted Medicaid expansion and 2) whether a state had adopted either Medicaid expansion, a family planning waiver, or a family planning SPA. We estimated dynamic and overall treatment effects using a novel difference-in-differences estimator that accounted for variation in treatment timing. Sensitivity analyses controlled for state-level characteristics including education, poverty, unemployment, race, ethnicity, migration, and population size change.

Data Sources and Analytic Sample:

Data were collected from CDC surveillance reports and 1-year American Community Survey files from 2008-2022.

Principal Findings:

Pre-treatment trends in CS outcomes were similar between states that implemented the Medicaid policies and those that did not. Medicaid expansion alone was associated with a significant reduction of 6.37 (95% CI: 1.94, 10.79) cases per 100,000 live births over the first three years of the policy. Adopting either Medicaid expansion, a family planning SPA, or a family planning waiver was related to a non-

significant reduction of 5.06 (95% CI: -3.21, 13.33) cases per 100,000 live births. Significant reductions in CS were also found within the first year of policy adoption.

Conclusions:

This analysis found Medicaid expansion policies were associated with reductions in CS rates. Increasing access to family planning services through Medicaid programs might reduce CS even shortly after policy adoption.

Introduction

Addressing the rise in rates of congenital syphilis (CS) is an urgent public health priority.[1] CS occurs when syphilis is vertically transmitted to a fetus during pregnancy and is prevented through diagnosis and treatment of syphilis before or early during pregnancy. Untreated syphilis can have severe health consequences, including neurologic changes and permanent vision and hearing loss for infants in addition to impacting pregnancy outcomes.[2] Reported cases of CS in the United States have increased an alarming 10-fold over the past decade to 3,755 cases in 2022.[1,3] CS is associated with spontaneous abortion, stillbirth, infant death, pre-term delivery, low birth weight, and long-term health impacts for surviving infants.[1,4] Further, hospitalizations attributable to CS have high direct medical costs.[5,6]

A variety of factors may be contributing to the syphilis and CS epidemics, and studying their social, behavioral, and clinical determinants might yield critical information for controlling the rise of syphilis and CS.[1,2] First, rates of CS are closely related to rates of primary and secondary (P&S) syphilis in women of reproductive age (15-44 years), so factors contributing to the rise in P&S syphilis in this population are relevant.[3] There is evidence of increases in sexual behaviors that are associated with STIs: condom use

53 has fallen among some groups in recent years,[7,8] and there may be changes in safe-sex behaviors in
54 response to falling HIV mortality. [9] Changes in technology may be altering the composition of sexual
55 networks,[10] which are a critical component of sexually transmitted infection (STI) transmission. Trends in
56 opioid use, methamphetamine use, and transactional sex may also be contributing to the rise in syphilis
57 in the U.S.[11,12] Further, healthcare disruptions during the COVID-19 pandemic likely led to reductions in
58 STI services.[13]

59

60 Since 2010, substantial changes to the U.S. healthcare landscape, including family planning services (e.g.,
61 contraception, STI services, and preconception services), also have possible implications for syphilis and
62 CS. Starting in 2014, as part of the Affordable Care Act (ACA), many states and the District of Columbia
63 (D.C.) expanded eligibility for full-benefit Medicaid, i.e., comprehensive insurance that covered all
64 mandatory Medicaid benefits.[14] Medicaid, the primary funding source for family planning services for
65 people with low incomes, has established minimum federal standards for family planning services and
66 supplies, with states able to set eligibility levels and determine the amount, duration, and scope of
67 covered benefits within broad federal parameters.[15,16] The ACA required many group and individual
68 health plans (i.e., private insurance) and Medicaid plans to cover preventive services without cost
69 sharing, including FDA approved contraceptives, STI and HIV screenings, well-woman preventive visits,
70 breast and cervical cancer screenings, and HPV vaccination.[17,18]

71

72 In addition to full-benefit Medicaid expansion, limited-benefit Medicaid policies have extended eligibility
73 for family planning specific care since the 1990s. Medicaid section 1115 family planning demonstration
74 waivers are time-limited programs that extend coverage only for family planning services to additional
75 people low incomes who do not qualify for full-benefit Medicaid. Further, the ACA included a provision

76 for state plan amendments (SPAs) that enabled states to establish family planning expansion programs
77 by permanently amending their Medicaid state plan without the need for federal renewal.[19] Combined,
78 changes in these Medicaid policies led to substantial shifts in eligibility for family planning services
79 through Medicaid during 2008-2022.[20] Subsidies for directly purchasing private health insurance have
80 also made healthcare more affordable for women with low incomes during this period.[14] Public STI and
81 family planning clinics form additional key infrastructure for the family planning safety net in the U.S.,
82 but recent declines in other sources of federal and state funding to these clinics may have made revenue
83 from Medicaid relatively more important.[21,22]

84

85 Despite gains in health insurance coverage following the implementation of the ACA,[23] gaps in access
86 persist.[24] Increases in eligibility for Medicaid or subsidized health insurance do not always translate into
87 enrollment and utilization.[20] Persistent disparities and gaps in healthcare access likely mean continued
88 missed opportunities to prevent CS especially among certain groups. Racial, ethnic, and income
89 disparities in reported rates of syphilis have been documented, and rates are often increasing faster in
90 areas with higher levels of poverty.[25,26]

91

92 The objective of this analysis was to assess the relationship between the adoption of Medicaid expansion
93 policies and rates of CS in the United States. Numerous studies have explored the impact of Medicaid
94 expansion on a variety of health and economic outcomes.[27] However, the existence of limited-benefit
95 family planning waivers and SPAs might complicate the relevant timing of policy changes for sexual and
96 reproductive health outcomes affected by access to family planning services. For example, some states
97 that expanded full-benefit Medicaid in 2014 already had waivers or SPAs in place that extended access to
98 family planning services, meaning there was not have been a significant increase in eligibility for these

services when the state expanded Medicaid. Building on previous work that characterized the complex policy landscape,[20] we use quasi-experimental designs to analyze Medicaid's impact on CS. Our work highlights how adoption of Medicaid expansion policies might prevent CS and further costly downstream health outcomes.

Methods

To assess how Medicaid expansion policies impact reported rates of CS, we leveraged policy variation among states between 2008 and 2022 and implemented a novel estimator of difference-in-difference (DiD) that accounts for variation in treatment timing. There were two primary policy changes, or "treatments," of interest. Under the first, Medicaid expansion alone (ME), states were considered treated if they had implemented Medicaid expansion. Under the second, Medicaid expansion plus limited family planning policies (ME+LFP), states were considered treated if any of Medicaid expansion, a family planning waiver, or a family planning SPA were in place at any point in a given year. The treatment variable is binary where one means a state is treated in that year, and zero otherwise. Note that our treatment variables measure policy adoption, not actual healthcare utilization or access. States were considered treated based on policy implementation, regardless of subsequent enrollment levels or service utilization. This shifts the timing of treatment for states that have a limited-benefit family planning program in place at some point during the study period. In the analytic dataset, these treatment variables were coded as binary indicators taking the value of one if a state was treated during a given year and zero otherwise. States that experienced policy changes (e.g., ending a waiver program or transitioning between policy types) were coded according to their treatment status in each specific year. For the ME+LFP analysis, 26 states experienced treatment changes during the study period, with

most changes involving transitions to Medicaid expansion (n=16), followed by SPAs (n=7) and waivers (n=3). One state experienced multiple treatment changes during the study period.

DiD estimators use two types of comparisons to calculate treatment effects. First, outcomes within a state before treatment onset are compared to outcomes once treatment has begun. The change within a treated state is then compared to the concurrent change in states that were not treated during that same period (i.e., the controls). The controls included states during any years they were untreated. Specifically, states served as controls if they either: 1) never implemented the policy during the study period, or 2) had not yet implemented the policy in a given year.

There were two effect lengths highlighted in this analysis: the effect one year after the start of treatment and the overall effect, which used three years of post-treatment data unless otherwise noted. Three years was selected for the overall effect after treatment initiation for several reasons. First, expanding the treatment length would result in fewer states meeting the inclusion criteria, reducing the sample size as well as the precision of the estimates. For example, using a four-year window would exclude an additional three states that expanded Medicaid after 2019. Second, a three-year window provides sufficient time to observe policy effects while minimizing the influence of other concurrent policy changes or external factors that could affect outcomes. We therefore dropped treated states with fewer than three years of treated status in our main specification (n=2) to avoid changes in the effect due to compositional changes from differences in the set of states used to determine the 1-year versus overall effects. States that were always treated (e.g., had a waiver in place starting in 2008, n=21) were systematically dropped from the ME+LFP analysis because they do not have pre-treatment data and are not considered valid comparators. The preferred estimator for the DiD models was proposed by de

144 Chaisemartin and D'Haultfœuille (dCDH) and is well suited for this analysis because it accommodates
145 treatment switching and semi-continuous treatments, which were used in some sensitivity analyses.[28]

146

147 The primary model outcome is reported cases of CS per 100,000 live births. We hypothesized two basic
148 mechanisms through which family planning services might prevent cases of CS. First, STI testing and
149 treatment might reduce syphilis among women of reproductive age who are pregnant or who may later
150 become pregnant. Second, affordable access to contraception might reduce unintended pregnancies,
151 which may in turn reduce cases of CS. To test these hypotheses, we estimated models using two
152 additional outcomes: 1) the rate of primary and secondary (P&S) syphilis among women aged 15-24
153 years, and 2) total births per 1,000 women aged 15-19 years. Syphilis data were retrieved from the
154 National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention (NCHHSTP) AtlasPlus and live
155 birth outcomes from CDC Wonder.[29,30] Nearly half of reported STIs occur among adolescents and young
156 adults aged 15-24 years,[3] and this group is more likely to be enrolled in Medicaid.[31] Live birth data were
157 restricted to women aged 15-19 years because previous research found large effects of Medicaid family
158 planning policies within this group.[32]

159

160 We conducted a variety of sensitivity analyses. First, in place of a binary treatment indicator, the income
161 eligibility threshold for women without children (with the dCDH estimator) was used. Next, the
162 proportion of adult reproductive aged women (aged 18-44 years) who were eligible for family planning
163 services through Medicaid was estimated. The calculation of this variable is detailed in Williams et al.
164 (2024).[20] The effect of the size of the eligible population was estimated using an instrumental variables
165 estimator with year and state fixed effects, following Currie and Gruber (1996).[33] The instrumental
166 variable for a state's estimated eligible population was the national proportion of women that would be

eligible for Medicaid family planning if the state-level eligibility criteria were applied nationally. This strategy accounts for the possibility that state decisions to implement policies were in part based on state-specific demographic or economic trends, which would otherwise bias the estimated relationship. A one-year lagged version of this estimator was also utilized. We did not estimate a model with a lagged effect using the main specification because the dCDH estimator compares all other outcomes to the period just before initiation of treatment. If there is any effect in the first year, then that becomes the baseline in a lagged model and reduces estimated effects in later years. Next, additional models were estimated that included covariates, included states that had been recently (i.e., less than three years) treated, used four years of post-treatment data, or implemented the Callaway and Sant'Anna estimator.[34] For sensitivity analyses of the mechanism models, we estimated models with the following additional outcomes: P&S syphilis in women of reproductive age (15-44 years), overall live births (total births per 1,000 reproductive aged women), and the proportion of births to people with incomes below the poverty level. Analyses were conducted using Stata 18 and R version 4.4.0.

The instrumental variable models included a variety of control variables: the proportion of adult reproductive age women completing at least one year of higher education, mean income of adult reproductive age women as a proportion of the federal poverty level, the proportion of adult reproductive age women in households that received benefits from the Supplemental Nutrition Assistance Program (SNAP), the proportion of the state population that is unemployed, the proportion of the adult reproductive age female population that identifies as non-Hispanic Black, the proportion of the adult reproductive age female population that identifies as non-Hispanic White, the proportion of the adult reproductive age female population that identifies as Hispanic, the proportion of the state population that migrated from out of state in the past year, the annual percent change in state population, the proportion of the state population that is female, the proportion of the female

population that is between the ages of 15 and 24 years, and the proportion of the female population that is between the ages of 25 and 44 years. Covariate data were derived from American Community Survey data accessed via IPUMS.[35] Some covariate data were restricted to adult reproductive age women (i.e., 18-44 years) because it mirrors eligibility for some government programs, including family planning waivers in some states. The main dCDH specifications did not include covariates because 1) the assumptions of parallel trends appeared to be satisfied without covariates (i.e., we observed parallel trends in CS rates among treatment and non-treatment states prior to the onset of treatment), and 2) not all covariates could be used in some treatment years because of the relatively small number of control observations.[28]

Results

Twenty-seven states (including D.C.) expanded full-benefit Medicaid in 2014 (Supplemental Figure 1). Three more states expanded in 2015, two in 2016, two in 2019, and three in 2020. Oklahoma and Missouri expanded in 2021 but were not included in the main estimates because they did not have three years of post-treatment data at the time this study was conducted. Thus, there were 37 states that switched their treatment status under the ME treatment definition. For the ME+LFP treatment, 26 states switched their treatment status during the study period (Supplemental Figure 2). The relevant treatment change was Medicaid expansion in 16 states, SPAs in 7 states, and waivers in 3 states. Missouri and D.C. had state funded programs that provided similar levels of family planning benefits prior to Medicaid expansion and were thus designated as always-treated.[20] There were fewer total treatment changes under the ME+LFP definition because many expansion states already had waivers in place prior to 2008 and therefore did not experience a change in treatment status. For example, Illinois had a family planning waiver in place prior to 2008. When they expanded Medicaid in 2014, there was no change in

214 the ME+LFP treatment variable because they already had a Medicaid policy in place for family planning
215 services.

216

217 The mean rate of CS across states during 2008-2022 was 21.98 cases per 100,000 live births. There were
218 on average 6.38 cases of P&S syphilis per 100,000 women aged 15-44 years. Summary statistics for
219 additional outcome and control variables are presented in Table 1. There were no significant differences
220 in CS rates between treated and untreated states prior to Medicaid expansion (Figure 1). Using the main
221 model specifications, Medicaid expansion alone (ME) was associated with a reduction of 4.59 (95% CI:
222 1.62, 7.56) cases per 100,000 live births after one year and 6.37 (95% CI: 1.94, 10.79) cases per 100,000
223 live births overall (Table 2). Adopting Medicaid expansion, a family planning waiver, or a SPA (ME+LFP)
224 was associated with reductions of 3.37 (95% CI: 0.23, 6.51) cases per 100,000 and 5.06 (95% CI: -3.21,
225 13.33) cases per 100,000 after one year and overall, respectively.

226

227 Other treatment definitions resulted in similar CS rate reduction estimates, but only the lagged eligible
228 proportion estimate was statistically significant (3.73 cases per 100,000 overall effect, 95% CI: 0.58,
229 6.87). For secondary outcomes, there was some evidence of a reduction in P&S syphilis in women ages
230 15-24 (2.36 cases per 100,000 overall effect, 95% CI: 0.74, 3.97) and no evidence of an effect on live
231 births among women ages 15-19 (Table 3). The main results were generally robust when using
232 alternative models and specifications (Supplemental Table 1). The one-year effects were statistically
233 significant in all but one the CS outcome models, as were three of the five overall effects. The two
234 alternative live birth outcome models yielded no significant effect estimates.

235

236 **Discussion**

237 This analysis found robust evidence that Medicaid policies that increased eligibility for family planning
238 services were associated with declines in the rate of CS. Medicaid expansion alone was associated with a
239 significant reduction of over 6 cases per 100,000 live births compared to rates in non-expansion states,
240 equivalent to 29% of the mean rate of CS across states from 2008-2002. Medicaid expansion plus the
241 extension of family planning services through limited-benefit waivers or SPAs was associated with a
242 reduction of over 5 cases per 100,000 live births over three years of implementation, but the estimate
243 was not significantly different from zero. The difference in precision between the ME and ME+LFP results
244 does not necessarily mean that the family planning specific polices were themselves ineffective, rather
245 that the effect signal from the Medicaid expansion analysis, which didn't account for policies in place
246 prior to expansion, may have been stronger. There are a variety of reasons that may lead to less precise
247 effect estimates in our data. Limited-benefit waivers or SPAs, including those extending eligibility for
248 people who are pregnant or family planning, might be less publicized and well-known. Medicaid
249 expansion occurred in many states simultaneously and benefited from large scale outreach campagins.[36]
250 The heightened awareness might have led to more enrollment and service utilization. This is consistent
251 with previous work showing that even though higher pregnancy eligibility limits were in place prior to
252 implementation, Medicaid expansion improved timeliness and adequacy of prenatal care.[37] In addition,
253 in some states family planning program outreach was focused on existing clinic users.[19] This focus might
254 have resulted in a change in payer rather than increased utilization for those patients, although the influx
255 of Medicaid dollars might have expanded clinic capacity for future clients.[19] In addition, full-benefit
256 Medicaid expansion included access to additional preventive services beyond family planning, which
257 could have additional contributions to preventing CS.
258

259 The estimated effect on CS was statistically significant in the first year the policies were implemented
260 and grew slightly in magnitude over the first three years after policy adoption. Outreach and health
261 communication strategies in expansion states might have increased awareness of the upcoming policy
262 change and allowed people to quickly utilize the new benefits.[36] Given that diagnosing and treating
263 syphilis prior to pregnancy and early during pregnancy can be quickly accomplished when people
264 present to care,[1,2] it is reasonable that increasing access to clinical services that include syphilis
265 management would be able to prevent CS after just one year. The growing effect size over time is
266 unsurprising, as the prevention activities could impact pregnancy outcomes months to years after the
267 service was received. The instrumental variable estimates, using eligible population sizes, yielded
268 additional evidence to support a growing effect over time. In those sensitivity analyses, the estimated
269 effect was larger and more precise when the treatment variable was lagged one year.
270
271 We found that Medicaid expansion was associated with lowered P&S syphilis in women of reproductive
272 age, but we found no evidence of an association with live births. Lowering background rates of P&S
273 syphilis in women reduces the incidence of CS and its sequelae. Additionally, while access to affordable
274 contraception and preconception care could theoretically affect CS incidence in multiple ways, including
275 by reducing unintended pregnancy, our analysis found evidence only for reductions in P&S syphilis rates
276 as a potential mechanism. Previous evidence on the effect of limited family planning or full-benefit
277 Medicaid expansion on live birth outcomes has been mixed,[27] but some studies did find reductions in
278 births following the policy implementation.[32,38,39]
279
280 This analysis omits additional policy complexity that might be relevant for syphilis and CS outcomes.
281 States have phased out using waivers in favor of SPAs, but this analysis did not distinguish between those
282 two limited-benefit mechanisms and therefore might miss any potential benefits from switching to a

283 SPA. Medicaid eligibility extensions for people who are pregnant have been in place for decades.
284 However, pregnancy eligibility was fairly constant and did not vary substantially across states during the
285 time period of this analysis, so it should not impact the relevant timing of treatment in this analysis. In
286 addition, the ACA instituted marketplaces which may have facilitated access to insurance, required
287 private insurance plans cover certain family planning services, and extended dependent insurance
288 coverage until age 26. However, these changes were applied to all states simultaneously, so they should
289 not affect the DiD estimates. The Title X Family Planning Program, a domestic federal program dedicated
290 to ensuring access to high-quality, client-centered family planning care for millions of people with low
291 incomes or who are uninsured, may interact with Medicaid funding in complex ways but was omitted
292 from the current analysis.[22] Our treatment variables also capture policy adoption rather than actual
293 healthcare access or utilization. While policy implementation is necessary for expanding access to care,
294 other barriers such as awareness, enrollment processes, provider availability, and other factors can affect
295 whether eligible individuals ultimately receive services. Our estimates thus represent the intent-to-treat
296 effect of these policies rather than the effect of actually receiving services. While our 3-year post-
297 treatment window captured significant effects, longer-term impacts may differ. Additionally, the complex
298 nature of state policy changes, including transitions between different types of family planning coverage
299 and occasional policy reversals, required simplifying assumptions in our treatment coding that may not
300 fully capture all policy nuances. Finally, there is variation in state laws regarding the timing and frequency
301 of required screening for syphilis during pregnancy.[40]

302

303 This analysis provides new evidence on the potential impact of adopting Medicaid expansion policies on
304 CS prevention. Policymakers and public health professionals might consider these findings when
305 considering intervention alternatives for addressing the syphilis and CS epidemics. States could consider
306 the potential benefit of leveraging their Medicaid programs to reduce CS rates through expansion of

307 health insurance coverage, especially to people with low incomes who might not be able to otherwise
308 afford care, as well as the availability of low-cost family planning services. There are promising new
309 mechanisms for increasing eligibility for services through Medicaid that might be beneficial in CS
310 prevention among people who have limited access to social and medical services, including SPAs that
311 expand 12-month coverage during the postpartum period and section 1115 waivers that address health-
312 related social needs.[41] Further research might be beneficial to understand the complex relationships
313 between legislated policies and subsequent enrollment and utilization of services relevant for addressing
314 syphilis and CS. Mediating factors, such as health care workforce capacity, education efforts, and health,
315 also play important roles in the implementation and effectiveness of syphilis and CS prevention policies.

316 **References**

317 1. McDonald R, O'Callaghan K, Torrone E, et al. Vital Signs: Missed Opportunities for Preventing
318 Congenital Syphilis - United States, 2022. *MMWR Morb Mortal Wkly Rep*. Nov 17 2023;72(46):1269-
319 1274. doi:10.15585/mmwr.mm7246e1
320 2. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment
321 Guidelines, 2021. *MMWR Recomm Rep*. Jul 23 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1
322 3. Division of STD Prevention. National Center for HIV/AIDS VH, STD, and TB Prevention. Centers for
323 Disease Control and Prevention. *Sexually Transmitted Infections Surveillance, 2022*. 2024.
324 https://www.cdc.gov/std/statistics/2022/default.htm
325 4. Gomez GB, Kamb ML, Newman LM, Mark J, Broutet N, Hawkes SJ. Untreated maternal syphilis
326 and adverse outcomes of pregnancy: a systematic review and meta-analysis. *Bull World Health Organ*.
327 Mar 1 2013;91(3):217-26. doi:10.2471/blt.12.107623
328 5. Umapathi KK, Thavamani A, Chotikanatis K. Incidence Trends, Risk Factors, Mortality and
329 Healthcare Utilization in Congenital Syphilis-related Hospitalizations in the United States: A Nationwide
330 Population Analysis. *Pediatr Infect Dis J*. Nov 2019;38(11):1126-1130.
331 doi:10.1097/inf.0000000000002445
332 6. Owusu-Edusei KJ, Introcaso CE, Chesson HW. Hospitalization Cost of Congenital Syphilis
333 Diagnosis From Insurance Claims Data in the United States. *Sexually Transmitted Diseases*.
334 2013;40(3):226-229. doi:10.1097/OLQ.0b013e31827c5b9f
335 7. Copen CE, Dittus PJ, Leichliter JS, Kumar S, Aral SO. Diverging trends in US male-female condom
336 use by STI risk factors: a nationally representative study. *Sex Transm Infect*. Feb 2022;98(1):50-52.
337 doi:10.1136/sextrans-2020-054642
338 8. Lindberg LD, Firestein L, Beavin C. Trends in U.S. adolescent sexual behavior and contraceptive
339 use, 2006-2019. *Contraception: X*. 2021/01/01/ 2021;3:100064.
340 doi:https://doi.org/10.1016/j.conx.2021.100064
341 9. Yan X, Jia Z, Zhang B. Evaluating the risk compensation of HIV/AIDS prevention measures. *The*
342 *Lancet Infectious Diseases*. 2022;22(4):447-448. doi:10.1016/S1473-3099(22)00151-7
343 10. Ramchandani MS, Golden MR. Confronting Rising STIs in the Era of PrEP and Treatment as
344 Prevention. *Current HIV/AIDS Reports*. 2019/06/01 2019;16(3):244-256. doi:10.1007/s11904-019-00446-
345 5
346 11. Reno H, Fox B, Highfill C, et al. The Emerging Intersection Between Injection Drug Use and Early
347 Syphilis in Nonurban Areas of Missouri, 2012-2018. *J Infect Dis*. Sep 2 2020;222(Suppl 5):S465-s470.
348 doi:10.1093/infdis/jiaa056
349 12. Plotzker RE, Burghardt NO, Murphy RD, et al. Congenital syphilis prevention in the context of
350 methamphetamine use and homelessness. *Am J Addict*. May 2022;31(3):210-218.
351 doi:10.1111/ajad.13265
352 13. Rogers B, Tao J, Murphy M, Chan PA. The COVID-19 Pandemic and Sexually Transmitted
353 Infections: Where Do We Go From Here? *Sex Transm Dis*. Jul 1 2021;48(7):e94-e96.
354 doi:10.1097/olq.0000000000001445
355 14. French MT, Homer J, Gumus G, Hickling L. Key Provisions of the Patient Protection and Affordable
356 Care Act (ACA): A Systematic Review and Presentation of Early Research Findings. *Health Serv Res*. Oct
357 2016;51(5):1735-71. doi:10.1111/1475-6773.12511
358 15. Tsai D. *Medicaid Family Planning Services and Supplies: Requirements and Best*

359 *Practices*. 2024. https://www.medicaid.gov/federal-policy-guidance/downloads/cib08082024.pdf

16. Ranji U, Bair Y, Salganicoff A. *Medicaid and Family Planning: Background and Implications of the ACA*. 2016. https://www.kff.org/report-section/medicaid-and-family-planning-medicaid-family-planning-policy/

17. Ranji U, Gomez I, Salganicoff A, Rosenzweig C, Kellenberg R, Gifford K. Medicaid coverage of family planning benefits: findings from a 2021 state survey. 2022;

18. Health Resources & Services Administration. *Women's Preventive Services Guidelines*. 2024. https://www.hrsa.gov/womens-guidelines

19. Sonfield A, Gold RB. *Medicaid Family Planning Expansions: Lessons Learned and Implications for the Future*. 2011. https://www.guttmacher.org/sites/default/files/pdfs/pubs/Medicaid-Expansions.pdf

20. Williams AM, Saldarriaga EM, Cramer R. State-Level Trends in Access to Medicaid Family Planning Services, 2008-2023. *Health Services Research*. 2024 Oct 22 2024;doi:10.1111/1475-6773.14401

21. Leichliter JS, Heyer K, Peterman TA, et al. US Public STD Clinical Services in an Era of Declining Public Health Funding: 2013–14. *Sex Transm Dis*. 2017;44(8):505.

22. Clochard A, Killewald P, Larson A, et al. *Family Planning Annual Report: 2022 National Summary*. 2023. https://opa.hhs.gov/research-evaluation/title-x-services-research/family-planning-annual-report-fpar/fpar-archive

23. Courtemanche C, Marton J, Ukert B, Yelowitz A, Zapata D. Early Impacts of the Affordable Care Act on Health Insurance Coverage in Medicaid Expansion and Non-Expansion States. *J Policy Anal Manage*. winter 2017;36(1):178-210. doi:10.1002/pam.21961

24. Garfield R, Damico A, Orgera K. *The coverage gap: uninsured poor adults in states that do not expand Medicaid*. 2018. https://digirepo.nlm.nih.gov/master/borndig/101740265/Issue-The-Coverage-Gap-Uninsured-Poor-Adults-in-States-that-Do-Not-Expand-Medicaid.pdf

25. Smock L, Caten E, Hsu K, DeMaria A. Economic Disparities and Syphilis Incidence in Massachusetts, 2001-2013. *Public Health Reports®*. 2017;132(3):309-315. doi:10.1177/0033354916688269

26. Martin EG, Ansari B, Rosenberg ES, et al. Variation in Patterns of Racial and Ethnic Disparities in Primary and Secondary Syphilis Diagnosis Rates Among Heterosexually Active Women by Region and Age Group in the United States. *Sexually Transmitted Diseases*. 2022;49(5):330-337. doi:10.1097/olq.0000000000001607

27. Guth M, Diep K. *What Does the Recent Literature Say About Medicaid Expansion?: Impacts on Sexual and Reproductive Health*. 2023. https://www.kff.org/medicaid/issue-brief/what-does-the-recent-literature-say-about-medicaid-expansion-impacts-on-sexual-and-reproductive-health/

28. De Chaisemartin C, d'Haultfoeuille X. Difference-in-differences estimators of intertemporal treatment effects. *Review of Economics and Statistics*. 2024:1-45. doi:https://doi.org/10.1162/rest_a_01414

29. Centers for Disease Control and Prevention. NCHHSTP AtlasPlus. Accessed April 19, 2024, https://gis.cdc.gov/grasp/nchhstpatlas/main.html

30. Centers for Disease Control and Prevention. CDC WONDER. Accessed April 19, 2024, https://wonder.cdc.gov/

31. Foundation KF. Medicaid Enrollees by Age. Accessed January 13, 2025. https://www.kff.org/medicaid/state-indicator/medicaid-enrollees-by-age/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D

32. Kearney MS, Levine PB. Subsidized Contraception, Fertility, and Sexual Behavior. *Rev Econ Stat*. Oct 1 2009;91(1):137. doi:10.1162/rest.91.1.137

33. Currie J, Gruber J. Saving Babies: The Efficacy and Cost of Recent Changes in the Medicaid Eligibility of Pregnant Women *J Polit Economy*. 1996;104(6):1263-1296.

408 34. Callaway B, Sant'Anna PHC. Difference-in-Differences with multiple time periods. *Journal of*
409 *Econometrics*. 2021;225(2):200-230. doi:https://doi.org/10.1016/j.jeconom.2020.12.001
410 35. Ruggles S, Flood S, Sobek M, et al. Data from: IPUMS USA: Version 15.0. 2024. *Minneapolis, MN*.
411 doi:https://doi.org/10.18128/D010.V15.0
412 36. Artiga S, Rudowitz R, Tolbert J. *Outreach and Enrollment Strategies for Reaching the Medicaid*
413 *Eligible but Uninsured Population*. 2016. Accessed July 25, 2024. https://www.kff.org/medicaid/issue-
414 brief/outreach-and-enrollment-strategies-for-reaching-the-medicaid-eligible-but-uninsured-population/
415 37. Wherry LR. State Medicaid Expansions for Parents Led to Increased Coverage and Prenatal Care
416 Utilization among Pregnant Mothers. *Health Serv Res*. Oct 2018;53(5):3569-3591. doi:10.1111/1475-
417 6773.12820
418 38. Eliason EL, Daw JR, Allen HL. Association of Affordable Care Act Medicaid Expansions with Births
419 Among Low-Income Women of Reproductive Age. *J Womens Health (Larchmt)*. Jul 2022;31(7):949-956.
420 doi:10.1089/jwh.2021.0451
421 39. Lindrooth RC, McCullough JS. The effect of Medicaid family planning expansions on unplanned
422 births. *Womens Health Issues*. Mar-Apr 2007;17(2):66-74. doi:10.1016/j.whi.2007.02.012
423 40. Division of STD Prevention. National Center for HIV/AIDS VH, STD, and TB Prevention. Centers for
424 Disease Control and Prevention. State Statutory and Regulatory Language Regarding Prenatal Syphilis
425 Screenings in the United States. Accessed July 23, 2024, https://www.cdc.gov/std/treatment/syphilis-
426 screenings.htm
427 41. Hinton E, Diana A. *Section 1115 Medicaid Waiver Watch: A Closer Look at Recent Approvals to*
428 *Address Health-Related Social Needs (HRSN)*. 2024. https://www.kff.org/medicaid/issue-brief/section-
429 1115-medicaid-waiver-watch-a-closer-look-at-recent-approvals-to-address-health-related-social-needs-
430 hrsn/

431

Table 1: Mean and Standard Deviation of Outcome Variables and Covariates

Variable	Mean	Standard Deviation
Outcomes		
CS rate	21.98	41.68
Primary and secondary syphilis rate (ages 15-44)	6.38	11.81
Primary and secondary syphilis rate (ages 15-24)	6.35	10.55
Total births per 1,000 women (ages 15-44)	62.01	7.35
Total births per 1,000 women (ages 15-19)	24.39	11.57
Proportion of births to women below the FPL	7.56%	1.98%
Alternative Treatment Variables		
Income eligibility threshold as percentage of FPL (for women without children)	138.92	95.84
Eligible Proportion	37.21%	18.02%
Covariates		
Proportion receiving SNAP benefits*	16.85%	5.1%
Proportion completing at least 1 year of higher education*	62.67%	5.4%
Income as a proportion of the FPL*	2.90	29.65
Proportion migrating from out of state in past year	3.54%	1.34%
State unemployment rate	4.97%	1.78%
Proportion of population that is female	50.60%	0.85%
Population growth	0.67%	0.85%
Proportion identifying as Black, Non-Hispanic*	12.84%	11.17%
Proportion identifying as White, Non-Hispanic*	67.64%	16.16%
Proportion identifying as Hispanic*	12.91%	11.14%
Proportion of the female population aged 15-44 years	13.13%	0.98%
Proportion of the female population aged 25-44 years	25.81%	2.06%

*Among women aged 19-44 years
CS: congenital syphilis
SNAP: supplemental nutrition assistance program
FPL: Federal Poverty Level

443 **Table 2: Estimated change in the number of congenital syphilis cases per 100,000 live births after**
444 **implementation of Medicaid policies**

	Main analyses		**Sensitivity analyses**		
Treatment	**ME**: Medicaid expansion alone	**ME + LFP**: Medicaid expansion plus limited family planning policies	**Threshold**: Income eligibility threshold for women without children	**Eligibles**: Proportion eligible for family planning services through Medicaid	**Lagged Eligibles**: Previous year's proportion eligible for family planning services through Medicaid
One-Year Effect	**-4.59**	**-3.37**	-2.03		
[95% C.I.]	**[-7.56, -1.62]**	**[-6.51, -0.23]**	[-4.08, 0.03]		
Overall Effect	**-6.37**	-5.06	-3.31	-2.81	**-3.73**
[95% C.I.]	**[-10.79, -1.94]**	[-13.33, 3.21]	[-9.47, 2.86]	[-6.58, 0.96]	**[-6.87, -0.58]**

445 Bold indicates statistical significance at the 5% level.

446 ME: Medicaid expansion alone treatment definition (binary). Estimated using the dCDH method without
447 covariates.

448 ME + LFP: Medicaid expansion plus family planning waiver/state plan amendment treatment definition
449 (binary). Estimated using the dCDH method without covariates. See manuscript for an explanation of
450 why the estimated effect of Medicaid expansion alone (ME) is greater than the estimated effect for
451 Medicaid expansion plus limited family planning policies (ME + LFP).

452 Threshold: Continuous income eligibility threshold for women without children. Estimated using the
453 dCDH method without covariates. Coefficients represents the change in CS rate associated with a 100-
454 point increase in the income eligibility threshold.

455 Eligibles: The proportion of adult reproductive aged women eligible for family planning services through
456 Medicaid. Estimated using instrumental variables method with covariates. Coefficients represent the
457 change in CS rate associated with a 10-percentage point increase in the proportion of women eligible.

458 The overall effect used 3 years of post-treatment data for the ME, ME+LFP, and Threshold models, while
459 all available years of data were used for the Eligibles models.

460

Table 3: Estimated change in P&S syphilis and live births after implementation of Medicaid policies

	P&S Syphilis Rate (15-24)		Live Birth Rate (15-19)	
	ME: Medicaid expansion alone	ME + LFP: Medicaid expansion plus limited family planning policies	ME: Medicaid expansion alone	ME + LFP: Medicaid expansion plus limited family planning policies
One-Year Effect	**-1.66**	-0.76	0.07	-0.07
[95% C.I.]	**[-3.11, -0.21]**	[-2.37 0.84]	[-0.46, 0.60]	[-0.64, 0.49]
Overall Effect	**-2.36**	-1.54	0.14	-0.26
[95% C.I.]	**[-3.97, -0.74]**	[-4.93, 1.86]	[-0.62, 0.90]	[-1.16, 0.63]

461
462 Syphilis and live birth rates are among women. Bold indicates statistical significance at the 5% level. The
463 overall effect included 3 years of post-treatment data.
464
465 P&S: primary and secondary stages
466
467 ME: Medicaid expansion alone treatment definition. Estimated using the de Chaisemartin and
468 D'Haultfœuille (dCDH) method without covariates.
469
470 ME + LFP: Medicaid expansion plus family planning waiver/SPA treatment definition. Estimated using the
471 dCDH method without covariates.
472

473

474 **Figure 1: Event Study - Relationship between Medicaid Expansion and the Rate of Congenital Syphilis**



475

Supplemental Table 1: Alternative Models and Specifications for the Relationship between Medicaid Policies and CS, P&S Syphilis, or Live Births

	With Covariates	With Covariates	With MO and OK	4-Year Effects	Callaway and Sant'Anna	Live Births	Births	P&S Syphilis
Outcome	CS Rate	CS Rate	CS Rate	CS Rate	CS Rate	Overall Live Birth Rate	Births to Women in Poverty	P&S Rate in Women Aged 15-44
1-Year Effect	**-5.24**	**-4.28**	-2.51	**-3.53**	**-4.59**	-0.11	-0.23	**-0.86**
[95% C.I.]	**[-8.03, -2.45]**	**[-8.24, -0.32]**	[-5.85, 0.83]	**[-6.51, -0.55]**	**[-8.77, -0.41]**	[-0.45, 0.21]	[-1.34, 0.91]	**[-1.70, -0.01]**
Overall Effect	**-6.00**	-5.27	-4.88	**-4.64**	**-6.37**	-0.20	-0.50	**-1.95**
[95% C.I.]	**[-10.17, -1.83]**	[-12.98, 2.43]	[-10.10, 0.32]	**[-8.55, -0.74]**	**[-11.48, -1.25]**	[-0.67, 0.26]	[-1.51, 0.51]	**[-3.42, -0.49]**
Treatment	ME	ME + FP	ME	ME	ME	ME	ME	ME
Covariates	YES	YES	NO	NO	NO	NO	NO	NO

ME: Medicaid expansion alone treatment definition. Estimated using the dCDH method.
ME + LFP: Medicaid expansion plus family planning waiver/SPA treatment definition. Estimated using the dCDH method.
CS: Congenital Syphilis
P&S syphilis: Primary and secondary syphilis
Missouri (MO) and Oklahoma (OK) expanded Medicaid in 2021 and do not have 3 years of post-treatment data. Excluding them avoids compositional changes in the effect estimates. The overall effect included 3 years of post-treatment data for all specifications except in the 4-year effect column.

484 **Supplemental Figure 1: Timing of Medicaid Expansion by State**



485

486 ME: Medicaid expansion alone treatment definition.

487 **Supplemental Figure 2: Timing of Medicaid Family Planning Waivers, Medicaid Family Planning State Plan Amendments, and Full-Benefit**
488 **Medicaid Expansion, by State**



489

490 ME + LFP: Medicaid expansion plus limited-benefit family planning waiver/state plan amendment (SPA) treatment definition. When a state has
491 overlapping policies, the color refers to the first policy implemented.

492 **Supplemental Figure 3: Event Study - Relationship between Medicaid Expansion and Limited-Benefit**
493 **Family Planning Waivers/SPAs and the Rate of Congenital Syphilis**



494

495

496 **Supplemental Figure 4: Relationship between Medicaid Expansion and the Rate of Primary and**
497 **Secondary Syphilis among Women Aged 15-24**



498

499